cost is only that of the cheapest 250 kV set available, and the Co60 itself costs £150 for 60 c. This cost, every two years, is no more and probably much less than the average cost of tube replacements of most therapy machines, so that this unit is cheaper and easier to run than most conventional deep X-ray units. It needs very little more space or protection, so that there are no great installation costs.
Protection.-It was found that using 60 c of Co60, no added protection was needed other than a short brick wall to protect the entrance door of the room. Protection measurements gave quite low figures. The dose rate outside the room, near the control panel, is 0-1 of tolerance with the cobalt in the unit head, but twice tolerance while the cobalt is in transit between the safe and the unit head. The transit time is short, only a few seconds, so that no excess dosage is received by the operator of the unit. The effect on counting work with Geiger counters used near the treatment room is important. It was found that background counting was definitely affected, up to 50 yards distance in open air from the treatment room, but a much less distance if buildings were interposing.
There is a physics laboratory within 20 yards of the treatment room where the background radiation is not altered owing to the protection afforded by the building. Treatment applicators.-Co60 emits 2 gamma rays whose energies are 1 17 and 1-33 MeV, and has a H.V.L. of 10*6 mm. of Pb as calculated by Mayneord and Cipriani (1947) The half-value layer of this cobalt unit was measured by Merewether, Osborn and Wyard and was calculated to be 10-5 mm. of Pb. This unit, therefore, has an equivalent radiation to radium and supervoltage X-radiation of up to 3 MeV, and has a high output compared with conventional teleradium. At 8 cm. S.S.D. the skin dose rate was 180 r per minute. In a unit of this design the applicators, to give adequate protection, must be thick walled. The advantage of using uranium instead of tungsten Proceedings of the Royal Society of Medicine 16 alloy for this purpose is considerable. Uranium having a higher atomic number, i.e. 92, to tungsten 74, has about 20°, increase in absorption properties for radiation of H.V.L. 10-5 mm. Pb. In practice, this enabled the walls of the uranium applicator to be made 2 cm. less in diameter, still giving the same protection as tungsten applicators, and thus allowing greater ease of use in difficult sites. Due to the small size of the unit head and the great difficulty in obtaining uranium, only a limited number -of applicators were available at first and the maximum field size was small, being 8 cm. X 6 cm., the minimum 4 cm. X 4 cm. The high dose rate of 180 r per minute at 8 cm. S.S.D. enabled the treating distances to be increased and still have adequate dose rate. In order to increase the range of applicators, a number of brass extension applicators were made to fit on each uranium applicator. These extension applicators were made to fit the field sizes obtained at varying treatment distances for each uranium applicator. (Fig. 1 shows the unit head and extension applicators, one of which is in position for treatment.) These thin-walled extension applicators greatly increased the ease of treating difficult sites and enabled glancing and angled fields to be used, which previously had been impossible, due to the thickness of the uranium applicators. They also provided a wide range of field sizes at very little cost, ranging from 4 X 4 cm. at 8 cm. S.S.D. to a maximum of ______________________ .15 X 12 5 cm. at 20 cm. S.S.D. and at the same Godfrey of similar field sizes of 250 kV, H.V.L. 2-3 mm. Cu at 50 cm. F.S.D. and Co0 at 20 cm. S.S.D. There is very little difference between them, the depth doses being a little increased and a little flatter, using Co6". At 20 cm. S.S.D., the maximum field size is 15 X 12-5 cm. and with a skin dose rate of 20 r per minute. Similar depth dose curves are obtained to 250 kV therapy with the .0% -I -F,.
. --added advantage of increased skin tolerance and decreased bone absorption due to the high H.V.L. of the radiation. Increasing the treating distances brings improved depth doses but, of course, rapidly decreasing dose rates. Theoretically, it is possible to treat at 100 cm. S.S.D. and to have depth doses similar to that obtained from megacobalt units, but the output would be too small to be practicable. Decreasing the S.S.D. down to its minimum of 8 cm., correspondingly decreases the depth dose and increases the skin dose rate to 180 r per minute. Fig. 3 surface. The dose rate at the surface of a phantom is difficult to measure accurately with radiation of this energy. The skin dose was obtained indirectly by extrapolation, giving the broken curve of Fig. 4 which, if not the actual dose received at the surface of the skin, is a little greater than the build-up dose at 2 to 3 mm. deep. All skin dose rates have been correlated in this manner for all field sizes at all distances in order to prevent a false sense of security with skin doses which could not be accurate, and having an unknown greater dose just below the surface of the skin. Clinical use.-This is a treatment unit which, because of its high H.V.L., the high output at short distances, and the variability of the depth doses which can be obtained, has been found useful for many purposes. During the last three years this unit has been used for the following types of cases:
(a) Superficial lesions such as large skin epithelioma and breast tumours. (e) Sites of poor skin tolerance to irradiation, such as groin, axilla, vulva, skin over bone such as clavicle, and the skin of young children.
(f) Sites of high risk of necrosis, e.g. carcinoma of the pinna and recurrent growths in preirradiated areas, e.g. internal mammary gland metastases and skin nodules following post-operative radiotherapy for carcinoma of the breast and recurrent malignant glands of the neck and axillk.
(g) Because of the high dose rate at S.S.D.s resulting in short treatment times, a large number of patients can be treated daily by this unit. In practice we find that as many patients can be treated with this unit per day as with a 250 kV machine. Thus, besides radical treatments, there is time to treat many patients for whom palliation is all that can be hoped, and old patients who do not tolerate long treatment times.
This unit has been found useful for treating nearly all tumours in all sites of the body. Skin reactions, as expected, with radiation of H.V.L. 10-5 mm. Pb, are much less severe than with conventional deep X-ray therapy. The reactions have been rarely more than a brisk erythema, or a dry desquamation, with skin doses of 5,500 to 6,000 r in four to five weeks, even when given to groins and axillae, and therefore the amount of treatment given to any tumour has not been limited by skin reactions. For example, a patient who had one groin treated by deep X-ray therapy elsewhere to a dose of 6,000 r in four weeks and had developed a severe ulcerated reaction which had taken three months to heal, was referred for treatment to his other groin. He received a similar dose with this unit, 6,000 r in four weeks, and developed only a brisk erythema which had completely subsided in three weeks.
With skin doses of 5,000 to 6,000 r in four weeks, the skin reaction reaches its maximum one to two weeks following the end of treatment. With protracted treatments of 6,000 to 8,000 r in six to eight weeks, the skin reaction reaches its maximum before the end of treatment and begins to subside immediately treatment is completed. With the dose levels which have been used, no severe blistering reaction has occurred. The most severe reaction to date has been a patchy, moist desquamation. [Colour slides were shown to illustrate skin reactions produced at varying dose levels.]
There have not been, as yet, any cases of skin, bone or cartilage necroses, but enough time has not yet elapsed to exclude late necroses. One case of late subcutaneous induration has occurred due to the build-up dose beneath the skin surface. This type of reaction has been previously reported from the use of supervoltage radiation (Jones, 1948) . The reaction occurred in a woman aged 70 years who had palliative treatment to an inoperable carcinoma of the breast. A skin dose of 5,500 r in three weeks was given. She had a brisk erythema with dry desquamation only. Eighteen months after treatment there was no telangiectasia, but there was marked subcutaneous induration which first became apparent one year after treatment.
The unit has been in use for three years, which is too short a time to provide adequate statistical results. The results at short treatment distances appear to be similar to those obtained by teleradium treatment. At 20 cm. S.S.D., the results appear to be an improvement on those obtained by conventional deep X-ray therapy because of increased skin tolerance and decreased bone absorption.
At distances beyond 20 cm. results would be expected to begin to approach those obtained by megacobalt units and supervoltage X-ray units up to 3 MeV.
Conclusion.-The design of this unit is not ideal, having originally been designed for teleradium units. Many improvements could be produced by designing a unit specifically for use with 60 or more c of Co60; nevertheless, the unit has proved to be extremely useful. It has been economical, and has required very little maintenance. This type of unit would be an asset in most radiotherapy departments, especially to those, which, through lack of space or finance, are prevented from acquiring new buildings or very expensive machines such as megacobalt and supervoltage units. In departments which already have supervoltage X-ray therapy, a cobalt unit of this type would be useful for short 856 Section of Radiology 857 distance treatments only. It also has the great advantage of using amounts of Co60 which are available and can be supplied and renewed within our own country at the present time. POLYCYTHEMIA RUBRA VERA has been treated with radioactive phosphorus for three and a half years at The London Hospital and I shall discuss the results in 18 patients. A great deal more experience is needed before we can predict confidently the duration of the response to therapy.
Treatment of Polycythaemia Rubra Vera with Radioactive Phosphorus
The blood-volume changes in polycythwemia rubra vera: Dr. G. W. Boden suggested that a study of the blood volume might explain why patients often claim great relief after administration of radioactive phosphorus while measurements of hlmoglobin or red cell count show little change. So far 27 estimations of blood volume have been made on 11 patients. I shall describe first a mild case. His red cell count was about 6,500,000, the total blood volume was normal, the venous himatocrit was 52% instead of the usual 45%. 5 mc of p32 were given by intravenous injection. Four months later the venous hematocrit was 45 % and the blood volume was unaltered. After a year the figures are still normal, but the red cell volume has begun to rise, the venous hematocrit being 47 %. In this patient the blood volume did not change and was within normal limits and therefore the findings in venous blood-the red cell count and heematocrit-provided an accurate index of the effect of p32, In a more marked case the initial blood volume was above normal and haematocrit was 67 %. 5 mc of p32 caused a marked fall in red cell volume. The plasma volume increased and the total blood volume fell to normal limits. In this case the change in the total blood volume makes peripheral findings an inaccurate guide to the true extent of the improvement. Before treatment red cell volume in this patient was 180% of normal while the venous haematocrit was only 160% of normal. The change in total volume conceals about 20% of the alteration in red cell volume.
In a more severe case this effect may be very great, for example the third patient had severe polycythemia. His blood volume was very high at 7 litres with a high red cell count and a himatocrit of 74%. He was treated initially by venesection, 4 pints being removed during one month. Two months later his blood volume had hardly altered but the heematocrit and red cell count had fallen markedly. His symptoms were little changed. He was given radioactive phosphorus and four months later said he felt he was back to normal. There had been a slight further fall in the red cell count and hematocrit but his symptomatic relief was presumably mostly due to the dramatic fall in blood volume which was now within normal limits. For explanation see text.
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